Targeted protein degradation (TPD) is an emerging therapeutic modality with the potential to
tackle disease-causing proteins that have historically been highly challenging to target with …

Antagonism of protein–protein interactions (PPIs) with small molecules is becoming more
feasible as a therapeutic approach. Successful PPI inhibitors tend to target proteins …

Targeted protein degradation is a pharmacological modality that is based on the induced
proximity of an E3 ubiquitin ligase and a target protein to promote target ubiquitination and …

Targeted protein degradation induced by heterobifunctional compounds and molecular
glues presents an exciting avenue for chemical probe and drug discovery. To date, small …

The anticancer agent indisulam inhibits cell proliferation by causing degradation of RBM39,
an essential mRNA splicing factor. Indisulam promotes an interaction between RBM39 and …

DCAF1 is a substrate receptor of two distinct E3 ligases (CRL4DCAF1 and EDVP), plays a
critical physiological role in protein degradation, and is considered a drug target for various …

Human cytomegalovirus (HCMV) is an important pathogen with multiple immune evasion
strategies, including virally facilitated degradation of host antiviral restriction factors. Here …

HIV-1 encodes four" accessory proteins"(Vif, Vpr, Vpu, and Nef), dispensable for viral
replication in vitro but essential for viral pathogenesis in vivo. Well characterized cellular …

HIV-1 expresses several accessory proteins to counteract host anti-viral restriction factors to
facilitate viral replication and disease progression. One such protein, Vpr, has been …

AMBRA1 is a tumor suppressor protein that functions as a substrate receptor of the ubiquitin
conjugation system with roles in autophagy and the cell cycle regulatory network. The …